Obesity is defined as a BMI above 30 and is associated with increased risk of type 2 diabetes, heart disease, stroke, sleep apnea, and certain cancers. It results from a complex interaction of genetic, behavioral, and environmental factors.
Exenatide is a GLP-1 receptor agonist that stimulates insulin secretion, reduces appetite, and slows gastric emptying, used for type 2 diabetes and obesity.
Liraglutide is a GLP-1 receptor agonist that stimulates insulin secretion, reduces appetite, and slows gastric emptying, used for type 2 diabetes and obesity.
Semaglutide is a GLP-1 receptor agonist that stimulates insulin secretion, reduces appetite, and slows gastric emptying, used for type 2 diabetes and obesity.
Dulaglutide is a GLP-1 receptor agonist that stimulates insulin secretion, reduces appetite, and slows gastric emptying, used for type 2 diabetes and obesity.
Tirzepatide is a GLP-1 receptor agonist that stimulates insulin secretion, reduces appetite, and slows gastric emptying, used for type 2 diabetes and obesity.
Orlistat is used as an adjunct to diet and exercise for weight management in obese or overweight adults.
Describe your symptoms and get a structured AI clinical assessment — possible causes, urgency level, and recommended next steps.
Start Free AI Analysis →Content on this page is informed by evidence-based clinical sources including: